rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMRN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives

      MELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at maximising shareholder value. Strategic initiatives under consideration may include, but are not limited to mergers, acquisitions, licensing, or other strategic transactions. There can be no assurance that the strategic process will result in any tr

      Nov 10Yahoo FinanceIMRN
      Emerging Growth Research Reports Continued Revenue Growth at Immuron
      Nov 4MorningstarIMRN
      Immuron continued quarterly sales growth
      Oct 27Yahoo FinanceIMRN
      Immuron Cuts U.S. ATM Offering Capacity to $2 Million in Updated F-3 Filing

      Detailed price information for Immuron Ltd ADR (IMRN-Q) from The Globe and Mail including charting and trades.

      Oct 24The Globe and MailIMRN
      Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
      Oct 22Yahoo FinanceIMRN
      Travelan® Phase 2 Study Results Published
      Oct 13Yahoo FinanceIMRN
      Immuron Releases Comprehensive 2026 Annual Report

      Tipranks Press Release.

      Sep 25The Globe and MailIMRN
      Immuron Limited (IMRN) Presents at Coffee Microcaps Conference 2026 - Slideshow (NASDAQ:IMRN) 2026-09-22
      Sep 22Seeking AlphaIMRN
      12 Health Care Stocks Moving In Friday's Intraday Session
      Sep 4BenzingaGRIIMRN
      Digestive Health Expansion Sends This Microcap Soaring

      Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more

      Sep 4The Globe and MailIMRN
      Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement

      Immuron (NASDAQ:IMRN) has secured exclusive U. S.

      Sep 4Yahoo FinanceIMRN
      Immuron Stock Surges Friday: What's Driving the Action?
      Sep 4BenzingaIMRN
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Sep 4BenzingaAKANIMRN
      Immuron to launch PROIBS® in the United States

      MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26. The overall U.S. digestive/gut health supplement market is valued at $4.16 billion (Mordor Intelligence). Immuron is targeting a subset of this market with PROIBS®. PROIBS® is a medical device used for abdominal pai

      Sep 4Yahoo FinanceIMRN
      Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
      Sep 4BenzingaBTAIIMRN
      IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
      Sep 4Yahoo FinanceIMRN
      Immuron Reports FY26 Preliminary Results

      MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectationsIn February 2026 at the time the Company announced a Strategic Reset, 2H FY26 and FY26 Net Sales were projected to both exceed the prior comparative period (pcp) and Net Sales and Net Profit were all projected to exceed pcp. Immuron has exceeded sales projections with second half growth of

      Aug 28Yahoo FinanceIMRN

      This is the newest page. Registered accounts read further back.